首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Radiosynthesis,biological evaluation and preliminary microPET study of 18F-labeled 5-resorcinolic triazolone derivative based on ganetespib targeting HSP90
Authors:Julie Kang  Jun Young Lee  ?sa Ta?  Kunal N More  Hangun Kim  Jeong-Hoon Park  Dong-Jo Chang
Institution:1. College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon 57922,Republic of Korea;2. Radiation Instrumentation Research Division, Korea Atomic Energy Research Institute, Jeongeup 56212, Republic of Korea
Abstract:Heat-shock protein 90 (HSP90) is a molecular chaperone that activates oncogenic transformation in several solid tumors, including lung and breast cancers. Ganetespib, a most promising candidate among several HSP90 inhibitors under clinical trials, has entered Phase III clinical trials for cancer therapy. Despite numerous evidences validating HSP90 as a target of anticancer, there are few studies on PET agents targeting oncogenic HSP90. In this study, we synthesized and biologically evaluated a novel 18F-labeled 5-resorcinolic triazolone derivative (1, 18F]PTP-Ganetespib) based on ganetespib. 18F]PTP-Ganetespib was labeled by click chemistry of Ganetespib-PEG-Alkyne (10) and 18F]PEG-N3 (11) with 37.3?±?5.11% of radiochemical yield and 99.7?±?0.09% of radiochemical purity. 18F]PTP-Ganetespib showed proper LogP (0.96?±?0.06) and good stability in human serum over 97% for 2?h. 18F]PTP-Ganetespib showed high uptakes in breast cancer cells containing triple negative breast cancer (TNBC) MDA-MB-231 and Her2-negative MCF-7 cells, which are target breast cancer cell lines of HSP90 inhibitor, ganetespib, as an anticancer. Blocking of HSP90 by the pretreatment of ganetespib exhibited significantly decreased accumulation of 18F]PTP-Ganetespib in MDA-MB-231 and MCF-7 cells, indicating the specific binding of 18F]PTP-Ganetespib to MDA-MB-231 and MCF-7 cells with high HSP90 expression. In the biodistribution and microPET imaging studies, the initial uptake into tumor was weaker than in other thoracic and abdominal organs, but 18F]PTP-Ganetespib was retained relatively longer in the tumor than other organs. The uptake of 18F]PTP-Ganetespib in tumors was not sufficient for further development as a tumor-specific PET imaging agent by itself, but this preliminary PET imaging study of 18F]PTP-Ganetespib can be basis for developing new PET imaging agents based on HSP90 inhibitor, ganetespib.
Keywords:HSP 90  Tumor hypoxia  PET imaging  Ganetespib  TNBC breast cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号